Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Short Interest Update

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 10,430,000 shares, an increase of 28.9% from the March 31st total of 8,090,000 shares. Approximately 2.2% of the shares of the company are sold short. Based on an average daily trading volume, of 4,090,000 shares, the short-interest ratio is currently 2.6 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. B. Riley boosted their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research note on Tuesday, April 9th. Oppenheimer reissued an “outperform” rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Stock Up 3.8 %

Shares of CATX opened at 1.64 on Tuesday. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02. Perspective Therapeutics has a 1-year low of 0.21 and a 1-year high of 1.77.

Insider Transactions at Perspective Therapeutics

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Perkins Capital Management Inc. purchased a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $731,000. HighTower Advisors LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter worth approximately $314,000. Bank of New York Mellon Corp acquired a new position in Perspective Therapeutics in the 3rd quarter valued at $42,000. Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 8.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Simplicity Wealth LLC acquired a new stake in Perspective Therapeutics in the 1st quarter worth about $40,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.